APLN and pulmonary arterial hypertension: In animal models of PAH, a G protein biased apelin agonist with reduced potency at the β-arrestin pathway and therefore reduced likelihood of producing receptor desensitisation has been shown to be effective in attenuating the symptoms [42] and has been used in experimental human studies [43].